Royal Philips is showcasing its line of molecular imaging products at this week’s Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference in San Diego. The company, which introduced the first commercial time-of-flight PET/CT system 10 years ago, debuted its Veros digital-photon-counting PET/CT scanner at the SNMMI meeting.

Veros uses proton detection without the use of photomultiplier tubes while digital-photon counting converts scintillation light directly into a digital signal with zero analog noise. What’s more, 1:1 coupling of crystals to light sensors produces a linear count rate, faster time-of-flight performance, and sensitivity gains compared to analog.

Kirill Shalyaev, PhD, vice president and general manager of advanced molecular imaging at Philips, says this and other molecular imaging systems highlight the company’s dedication to “delivering health technology to drive better outcomes across the health continuum.” He adds: “Philips’ proven solutions and advanced innovations in molecular imaging are enabling fast and confident decision-making.”

Molecular imaging will play an even larger role in the health care industry as the population continues to age, especially as people more commonly have multiple chronic and complex diseases. As a result, analytics available in such technologies—such as time-of-flight, advanced data sharing, and the flexibility of PET/CT—will be crucial to improving patient care, Philips officials say.

For more information about these products, visit Philips Healthcare.